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Abstract
Background Tenapanor (RDX5791, AZD1722), a small
molecule with minimal systemic availability, is an inhibitor
of the sodium/hydrogen exchanger isoform 3 (NHE3).
Tenapanor acts locally in the gut to reduce absorption of
sodium and phosphate. It is being developed for the
treatment of patients with hyperphosphatemia in CKD
requiring dialysis and patients with constipation-predomi-
nant irritable bowel syndrome. We report the safety,
pharmacodynamics, and pharmacokinetics of tenapanor in
Japanese volunteers.
Methods In this phase 1, double-blind study
(NCT02176252), healthy Japanese adults (aged 20–45 years)
received single-dose tenapanor 180 mg (n = 6), repeated-
dose tenapanor 15, 30, 60, or 90 mg twice daily (n = 12 each)
for 7 days, or placebo (n = 14). All participants received a
standardized diet.
Results Single and repeated doses of tenapanor resulted in
higher mean stool sodium content vs. placebo (single dose,
41.9 mmol/day; repeated dose, range of means
21.3–32.2 mmol/day; placebo, 4.1 mmol/day) accompanied
by lower urinary sodium content (single dose, 110 mmol/-
day; repeated dose, 101–112 mmol/day; placebo,
143 mmol/day). Additionally, stool phosphorus content was
increased (single dose, 31.0 mmol/day; repeated dose,
17.6–24.8 mmol/day; placebo, 16.8 mmol/day) and urinary
phosphorus content decreased (single dose, 18.7 mmol/day;
repeated dose, 15.3–19.4 mmol/day; placebo, 25.5 mmol/-
day). Tenapanor had minimal systemic exposure, provided a
softer stool consistency, and was well tolerated.
Conclusions Tenapanor treatment reduced absorption of
intestinal sodium and phosphate from the gut in Japanese
adults. Tenapanor had minimal systemic exposure and was
well tolerated. Further research into the clinical benefits of
tenapanor is warranted.
Keywords Tenapanor  Sodium absorption  Phosphate
absorption  Sodium, dietary  NHE3 protein  Chronic
kidney disease
Introduction
Members of the sodium/hydrogen exchanger (NHE) family
of proteins, which are expressed throughout the gastroin-
testinal tract, facilitate the electro-neutral exchange of
sodium ions for intracellular hydrogen ions across mem-
branes [1]. NHE isoform 3 (NHE3) is particularly impor-
tant for intestinal sodium transport and subsequent fluid
homeostasis [2–4].
Tenapanor (RDX5791, AZD1722), a small molecule
with minimal systemic availability, is an inhibitor of NHE3
that acts locally in the gut [5]. Preclinical and early clinical
studies show that tenapanor reduces absorption of sodium
[5] and phosphate [6, 7] from the gut, with a concomitant
increase in stool fluid content. Sodium/fluid and phosphate
imbalances play a role in many conditions, such as
hypertension, heart failure, and chronic kidney disease
(CKD) [8–14], and stool consistency is of relevance in
constipation-related disorders.
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In an animal model of CKD (5/6 nephrectomized rats
fed a high-salt diet), tenapanor treatment provided protec-
tive effects on renal function and reduced extracellular
fluid volume and blood pressure [5]. In addition, an animal
model of uremic calcification demonstrated that tenapanor
treatment reduced vascular calcification [6]. In healthy
volunteer studies, tenapanor treatment over 7 days reduced
sodium absorption, resulting in increases in stool sodium
content of up to 50 mmol (2.9 g table salt) per day [5].
The most recent guidelines on the treatment of patients
with CKD from the Japanese Society of Nephrology
(published in 2013) recommend restriction of dietary
sodium intake to 2.4 g (approximately 6 g table salt) per
day [15], and the American Heart Association recommends
restriction of sodium intake to 1.5 g (3.8 g table salt) per
day in the general population [11]. There are currently no
approved drugs that reduce sodium absorption. Therefore,
the only means by which sodium uptake can be controlled
is by diet, which is often ineffective.
Tenapanor is being evaluated for the treatment of
patients with hyperphosphatemia in CKD requiring dialysis
and patients with constipation-predominant irritable bowel
syndrome (IBS). As a component of its clinical develop-
ment program, it is important to evaluate the clinical
pharmacology of tenapanor in Japanese individuals, so that
the agent may be made available for the treatment of
patients with these conditions in Japan in the future. Here,
we report data from the first study of tenapanor in a
Japanese population. This study evaluated the safety, tol-
erability, pharmacodynamics, and pharmacokinetics of
tenapanor in healthy volunteers.
Materials and methods
Study design
This was a phase 1, double-blind, randomized, placebo-
controlled study in healthy Japanese adult volunteers
(ClinicalTrials.gov identifier: NCT02176252). A group of
healthy Caucasian individuals was included, primarily to
collect further safety data on tenapanor at the highest dose
in Caucasian people. The study was conducted at a clinical
pharmacology unit (CPU) at WCCT Global, Cypress, CA,
USA. The study protocol and consent forms were reviewed
and approved by the Institutional Review Board Aspire
IRB, Santee, CA, USA (approval number D5611C00005)
before commencement of the study.
After screening, eligible participants were admitted to
the CPU 2 days before assignment to treatment. Japanese
participants were allocated sequentially in the order of
completion of their screening assessments to groups
evaluating tenapanor hydrochloride (hereafter referred to
as tenapanor) given as a single 180 mg dose or one of four
repeated doses (tenapanor 15, 30, 60, or 90 mg twice daily
over 7 days). Within the single-dose group, participants
were randomly assigned to tenapanor (180 mg) or placebo
in a 3:1 ratio. Within the repeated-dose groups, participants
were randomly assigned to tenapanor or placebo, all twice
daily for 7 days, in a 4:1 ratio. Caucasian participants were
randomly assigned to either tenapanor 90 mg or placebo,
both twice daily for 7 days, in a 4:1 ratio. Data from the
single-dose group was obtained before commencing repe-
ated dosing. The repeated-dose 15–60 mg twice-daily
groups were run in parallel to each other. All safety data
were evaluated before dose escalation to the highest repe-
ated dose of 90 mg twice daily.
A follow-up visit was scheduled for each participant
7–10 days after discharge from the CPU (on day 2 for the
single-dose group and day 8 for the repeated-dose
groups).
Participants
This study was conducted in accordance with the Decla-
ration of Helsinki. All participants provided written
informed consent. Men and women could be included if
they were aged 20–45 years with a body mass index of
19–27 kg/m2 and a weight of 45–100 kg. All participants
had to be healthy, as judged by their medical history,
laboratory screening, physical examination, and 12-lead
paper electrocardiography (ECG). To be considered Japa-
nese, both of an individual’s parents and both pairs of
grandparents had to be Japanese, and the individual must
have been born in Japan and must not have lived outside
Japan for more than 5 years.
Individuals were excluded if they: had a history or
presence of gastrointestinal, hepatic, or renal disease,
including gastrointestinal surgery (other than appendec-
tomy) or any other condition known to interfere with
absorption, distribution, metabolism, or excretion of drugs;
had loose stools (Bristol Stool Form Scale [BSFS] [16]
score of 6 or 7) for 2 or more days in the 7 days before
randomization; had used medications known to affect stool
consistency and/or gastrointestinal motility during the
7 days before assignment to treatment; or had used elec-
trolyte supplements containing sodium, potassium, chlo-
ride, or bicarbonate during the 7 days before assignment to
treatment. All participants were expected to abstain from
taking any medication (prescribed or over-the-counter
products), other than paracetamol/acetaminophen, hor-
mone-replacement therapy and oral contraceptives, from
2 weeks before the first administration of investigational




Tenapanor was available in 15, 30, or 60 mg non-formu-
lated capsules. In the single-dose (180 mg) group, tena-
panor or corresponding placebo capsules were
administered orally 5–10 min before breakfast. In the
repeated-dose groups, tenapanor or corresponding placebo
capsules were administered orally 5–10 min before
breakfast and dinner.
While in the CPU, including during the 2-day run-in
period, participants received a standardized diet with an
approximate sodium content of 4.5 g (195 mmol) per day
[1.5 g (65 mmol) in each of three daily meals], equivalent
to 11.4 g of table salt per day. Phosphate content of meals
was not standardized; however, all individuals received the
same meals on the same study days, thereby facilitating
consistent phosphate intake. Participants did not have
access to table salt or sodium-containing sauces and spices
during meals. Fluid intake was ad libitum.
Study assessments
Adverse events were recorded throughout the study. Vital
signs were recorded before the first dose of study drug, on
study days 1 and 2 (all treatment groups), and on day 8
(repeated-dose groups). Physical examinations were con-
ducted at screening, on study day 1 (all groups), on day 8
(repeated-dose groups), and at the follow-up visit (all
groups). Digital ECG measurements were recorded on
study days 1 and 2 (all groups) and days 7 and 8 (repeated-
dose groups). Safety laboratory evaluations (fasting state)
were made on study day 1 (all treatment groups), day 2
(single-dose group), and day 8 (repeated-dose groups).
Pharmacodynamic measures included daily stool and
urinary sodium and phosphorus content and daily stool
frequency, weight, and consistency (as measured by BSFS
score on the 7-point scale from type 1 [hard lumps] to type
7 [watery] [16]). Bowel movement assessments were per-
formed and daily urine samples collected from the day
before assignment to treatment (day -1) to the day after
receiving the last dose. The daily collection intervals began
after the morning dose on one day and ended just before
the morning dose on the next day; for days when no dose
was administered, the time that the morning dose would
have been administered was used.
Plasma concentrations of tenapanor were determined
from blood samples collected pre-dose and 1, 2, 4, 8, and
24 h post-dose on day 1 for the single-dose group, and pre-
dose and 1, 2, 4, and 8 h after the morning dose on days 1
and 7 for the repeated-dose groups.
Analytical methods
Plasma concentrations of tenapanor were measured by
MicroConstants, Inc. (San Diego, CA, USA). Human
plasma samples containing tenapanor, its deuterated analog
as the internal standard, and dipotassium ethylenedi-
aminetetraacetic acid as the anticoagulant were processed
first by protein precipitation followed by back extraction
into an acidic aqueous solution. The extracts were injected
and analyzed by reversed-phase high-performance liquid
chromatography using a Synergi Hydro-RP column (Phe-
nomenex, Torrance, CA, USA) maintained at 35 C. The
mobile phase was nebulized using heated nitrogen in a
Z-spray source/interface set to electrospray positive-ion-
ization mode. The ionized compounds were quantified
using mass spectrometry (MS/MS). The lower and upper
limits of quantification were 0.5 and 500 ng/mL, respec-
tively. The accuracy (variation in measured concentration
compared with theoretical concentration) and precision
(coefficient of variation [SD/mean] within replicates) of
quality-control standards of tenapanor were determined at
concentrations of 0.5, 1.5, 20, and 400 ng/mL. Accuracy
and precision were in the ranges of -1.5 to 8.0 and
2.8–9.1 %, respectively. Precision and accuracy no greater
than 20 % were required for quality-control standards at
the lower limit of quantification.
Sodium and phosphorus content of stool samples was
determined by RTI International (Research Triangle Park,
NC, USA). Stool samples were transferred to the laboratory
in a frozen state and stored at -20 C. Samples were
partially digested in approximately twice their weight of
concentrated nitric acid and then heated at 60 C for 3 h;
aliquots of the resulting partially digested samples (5 mL)
were further digested with nitric and hydrochloric acids
and diluted to 50 mL with deionized water, before cen-
trifugation to precipitate insoluble matter. The sodium and
phosphorus content of the supernatant liquid was measured
using inductively coupled plasma-optical emission spec-
trometry (iCAP 6500 ICP-OES analyzer, Thermo, USA).
The validated lower limit of quantification was defined by
the lowest replicate electrolyte concentration that was
measured with acceptable accuracy (±20 % of the nominal
back-calculated concentration from the calibration curve).
At least four of six quality-control standards had to be
quantified as within 20 % of their theoretical value for an
analysis run to be acceptable. The overall precision and
overall bias (a measure of accuracy) of the assay for
sodium, as determined by analysis of quality-control
standards were in the ranges of 3.2–5.8 % and 2.9–14.5 %,
respectively. The overall precision and overall bias of the
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assay for phosphorus were in the ranges of 1.9–3.3 and
0.4–3.8 %, respectively.
Sodium and phosphorus content of urine samples were
determined using ion selective electrode measurements by
standard clinical laboratory techniques (Consolidated
Medical Bioanalysis, Cypress, CA, USA).
Statistical analyses
Pharmacodynamic measurements were summarized
according to dose group using descriptive statistics, with
calculations of daily means and standard deviations
across the treatment period. For each participant, mean
on-treatment daily stool and urinary sodium and phos-
phorus content and daily stool frequencies were calcu-
lated as the mean of all available measurements
following assignment to treatment divided by the num-
ber of days of treatment for which measurements were
available. For each individual, mean BSFS score and
mean stool weight were calculated as the mean for each
24-h period, and the 24-h means over the full treatment
period were used to provide the mean daily BSFS score
and mean daily stool weight. Statistical analyses were




Of the 144 people screened, 83 healthy Japanese and
Caucasian individuals were assigned to treatment. The
demographic and baseline characteristics of the partici-
pants were generally well balanced across the treatment
groups (Table 1). The study population included 68 Japa-
nese individuals. Of these, 65 completed the study: two
individuals (one each from the single-dose tenapanor
180 mg group and the repeated-dose tenapanor 15 mg
twice-daily group) withdrew from the study during the
follow-up period, both due to relocation, after having
received all specified doses of tenapanor according to
protocol. A third Japanese individual in the placebo group
withdrew 3 days after randomization (participant decision).
There were 15 Caucasian individuals who were assigned to
treatment (12 to tenapanor and three to placebo), all of
whom completed the study.
Safety and tolerability
Tenapanor was generally well tolerated. Overall, a total of
16 individuals (11 Japanese and five Caucasian) reported at
least one adverse event during the study, irrespective of the






180 mg (n = 6)
Tenapanor 15 mg
b.i.d. (n = 12)
Tenapanor 30 mg
b.i.d. (n = 12)
Tenapanor 60 mg
b.i.d. (n = 12)
Tenapanor 90 mg
b.i.d. (n = 12)
Age (years) 37.5 ± 8.7 35.4 ± 5.8 33.2 ± 6.7 30.3 ± 5.5 29.3 ± 8.1 30.9 ± 8.0
Men (n) 1 7 11 7 9 10
Height (cm) 161 ± 5 167 ± 8 172 ± 7 167 ± 7 171 ± 9 169 ± 8
Weight (kg) 54.8 ± 7.4 62.0 ± 9.2 69.9 ± 9.0 61.8 ± 9.0 66.1 ± 11.7 64.3 ± 8.4
Body mass
index (kg/m2)




0.77 ± 0.16 0.84 ± 0.14 0.93 ± 0.14 0.73 ± 0.17 0.86 ± 0.17 0.82 ± 0.11
Caucasian individuals receiving tenapanor 90 mg b.i.d (n = 12):a age, 33.3 ± 7.4 years; men, n = 8; height, 171 ± 9 cm; weight,
70.8 ± 11.0 kg; body mass index, 24.1 ± 2.3 kg/m2; serum creatinine, 0.93 ± 0.19 mg/dL
Caucasian individuals receiving placebo (n = 3):a age, 27.7 ± 2.1; men, n = 2; height, 167 ± 10 cm; weight, 65.3 ± 8.9 kg; body mass index,
23.5 ? 3.1 kg/m2; serum creatinine, 0.90 ± 0.20 mg/dL
Data are shown as mean ± standard deviation, unless otherwise stated
b.i.d. twice daily
a Dosing over 7 days
b Combined data from Japanese participants receiving single (n = 2) and repeated (n = 12) doses
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relationship to treatment. This included four individuals
receiving placebo (three Japanese and one Caucasian). All
reported adverse events were mild, with no serious adverse
events or discontinuations due to adverse events.
In Japanese individuals, three adverse events in partic-
ipants receiving tenapanor were judged to be related to
treatment by the study investigator. These consisted of two
events of diarrhea (60 and 90 mg twice daily, one per
group) and one event of nausea (90 mg twice daily). In
Caucasian individuals treated with tenapanor 90 mg twice
daily, four adverse events were also judged as being related
to treatment by the study investigator, consisting of one
event of abdominal pain, two events of diarrhea, and one
event of headache.
Across all treatment groups, there were no clinically
relevant changes noted amongst individuals receiving sin-
gle- or repeated-dose tenapanor or placebo in laboratory
assessments, vital signs, ECG parameters, or physical
examinations (see Supplementary Table S1 for data on







































































































Fig. 1 Excretion of sodium via
a stool and b urine in healthy
Japanese volunteers treated with
tenapanor or placebo. Data are
shown as mean ? SD;
corresponding values given
above the bars show mean
(SD). a daily mean over
7 days. b combined data from
participants receiving single
(n = 2) and repeated (n = 12)
doses (one individual in the
placebo group was excluded
from stool analyses owing to a
lack of any post-baseline




Sodium and phosphorus excretion
Stool and urinary sodium content in Japanese individuals
following single or repeated doses of tenapanor or pla-
cebo are shown in Fig. 1. Twice-daily treatment with
tenapanor 15–90 mg for 7 days resulted in mean stool
sodium content in the range of 21.3–32.2 mmol/day, with
corresponding mean urinary sodium content in the range
of 101–112 mmol/day. Variability across the cohorts was
high with regard to stool sodium content, with coefficients
of variation in the range of 51–84 %; the coefficients of
variation were lower for urinary sodium content
(17–32 %). Repeated-dose tenapanor resulted in increases
in stool sodium content of 17.2–28.1 mmol/day relative to
placebo (Fig. 1a) and decreases in urinary sodium content
of 31.1–41.4 mmol/day relative to placebo (Fig. 1b). Data
from the repeated-dose groups did not support a dose–
response relationship with regard to stool and urinary
sodium content when data were viewed as the mean


















































































































Fig. 2 Excretion of phosphorus
via a stool and b urine in
Japanese healthy volunteers
treated with tenapanor or
placebo. Data are shown as
mean ? SD; corresponding
values given above the bars
show mean (SD). a daily mean
over 7 days. b combined data
from participants receiving
single (n = 2) and repeated
(n = 12) doses (one individual
in the placebo group was
excluded from stool analyses
owing to a lack of any post-




day-by-day, where the effects of variation are greater
(data not shown).
Stool and urinary phosphorus content in Japanese indi-
viduals following single- or repeated-dose tenapanor or
placebo are shown in Fig. 2. Relative to placebo, repeated-
dose tenapanor resulted in increases in stool phosphorus
content of 0.8–8.0 mmol/day (Fig. 2a) and decreases in
urinary phosphorus content of 6.1–10.2 mmol/day
(Fig. 2b). Data from the repeated-dose groups did not
support a dose–response relationship with regard to stool
and urinary phosphorus content.
In the Caucasian cohort, similar trends of increases in
stool sodium and phosphorus content and decreases in
urinary sodium and phosphorus content relative to placebo
were also observed with repeated-dose tenapanor 90 mg
twice daily over 7 days. In individuals receiving tenapanor
or placebo, stool sodium content was (mean ± SD)
17.2 ± 10.8 and 3.1 ± 3.7 mmol/day, respectively, and
urinary sodium content was 76.6 ± 35.6 and
80.0 ± 22.3 mmol/day, respectively. Corresponding stool
phosphorus content was (mean ± SD) 18.8 ± 9.5 and
14.8 ± 5.3 mmol/day, respectively, and urinary phospho-
rus content was 16.1 ± 3.5 and 21.9 ± 1.6 mmol/day,
respectively.
Stool frequency, weight, and consistency
The effects of tenapanor on stool frequency, weight, and
consistency are shown in Table 2. Twice-daily dosing with
tenapanor 15–90 mg resulted in stool frequencies in the
range of 1.8–2.1 bowel movements/day, compared with
1.4 bowel movements/day for placebo. An increase in stool
weight was also observed, with mean values in the range of
118–134 g/day with tenapanor 15–90 mg, compared with
108 g/day for placebo. Softening of the stool was observed
when the participants were treated with tenapanor com-
pared with placebo: mean daily BSFS scores were in the
range of 4.4–5.4 in individuals treated with twice-daily
tenapanor 15–90 mg, compared with 3.4 for those treated
with placebo.
A similar trend of increased stool frequency and stool
weight, accompanied by a softening of stool was also
observed in Caucasian individuals, who received tenapanor
90 mg twice daily over 7 days.
Pharmacokinetics
After treatment with single-dose tenapanor 180 mg, the
plasma concentration of tenapanor was below the lower
limit of quantification (0.5 ng/mL) in 28 of 30 post-dose
plasma samples. Two samples had plasma tenapanor con-
centrations of 0.58 and 0.70 ng/mL, both of which were
taken (from separate individuals) at 4 h post-dose. After
repeated twice-daily dosing with tenapanor (15–90 mg) for
7 days, the plasma concentration of tenapanor was below
the lower limit of quantification in 539 of 540 post-dose
samples. One sample from a Japanese individual receiving
tenapanor 60 mg twice daily had a plasma tenapanor
concentration of 0.51 ng/mL, which was taken 4 h post-
dose on the first day of treatment.
Discussion
This article reports the first study of Japanese individuals
who received tenapanor, a small-molecule inhibitor of
NHE3 that acts locally in the gut with minimal systemic
drug exposure. Our study, in which participants received a









b.i.d. (n = 12)
Tenapanor 30 mg
b.i.d. (n = 12)
Tenapanor 60 mg
b.i.d. (n = 12)
Tenapanor 90 mg
b.i.d. (n = 12)
Stool frequency (bowel
movements/day)
3.8 ± 2.3 1.8 ± 1.1 2.1 ± 0.7 1.8 ± 0.7 1.9 ± 0.7 1.4 ± 0.5
Stool weight (g/day) 127 ± 60 118 ± 31 134 ± 42 134 ± 79 132 ± 67 108 ± 47
Stool consistency (mean
daily BSFS score)
5.2 ± 2.0 4.4 ± 1.4 5.1 ± 1.3 5.4 ± 0.9 5.4 ± 0.8 3.4 ± 0.5
Data shown are mean ± standard deviation over the treatment period (1 or 7 days for single- or repeated-dose groups, respectively)
b.i.d. twice daily, BSFS Bristol Stool Form Scale
a Dosing over 7 days
b Combined data from Japanese participants receiving single (n = 2) and repeated (n = 12) doses
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standardized diet, showed that administration of tenapanor
over a wide dose range reduced the absorption of dietary
sodium and phosphate in Japanese individuals, as demon-
strated by increases relative to placebo in stool sodium and
phosphorus content and concomitant decreases in urinary
sodium and phosphorus content.
With the exception of the lowest dose (15 mg twice
daily over 7 days), all other repeated doses of tenapanor
(up to 90 mg twice daily over 7 days) resulted in mean
daily stool sodium excretion of approximately 30 mmol/-
day, compared with 4 mmol/day with placebo treatment.
Stool sodium excretion of 30 mmol is equivalent to
approximately 1.8 g of table salt, or 16 % of the 11.4 g of
table salt consumed daily by the study participants. It is
important to note, however, that although the mean of stool
and urinary electrolyte content was calculated over the
whole treatment period, there was large variability in stool
sodium content across the cohorts. Less variability across
the cohorts was evident with urinary sodium content.
Repeated-dose tenapanor resulted in similar stool phos-
phorus (approximately 18–25 mmol/day) and urinary
phosphorus (15–19 mmol/day) content, irrespective of
dose. Tenapanor treatment also resulted in increases in
stool frequency and weight and a softer stool consistency.
The pharmacodynamic data for tenapanor in Japanese
individuals are in line with previously reported data in a
population of mainly Caucasian and African-American
healthy volunteers who received repeated-dose tenapanor:
in these individuals, increases in stool sodium [5] and
phosphorus [7] content, and decreases in urinary sodium
and phosphorus content of broadly similar respective
magnitudes, were observed. Consistent with data from the
same studies [5], tenapanor was quantifiable in fewer than
1 % of measured serum samples collected from Japanese
individuals.
Interestingly, it was noted that in some treatment groups
in our study, levels of sodium excreted in stool and urine
did not add up numerically to the total sodium intake.
While some variability in the collection of urine and stool
samples and their analyses could have contributed to this
observation, the finding is in line with that of another study
conducted in a highly controlled environment, in which
sodium excretion at constant sodium intake showed weekly
rhythms, resulting in periodic storage of sodium in the
body [17].
Excessive sodium intake [8, 11] and fluid overload
[10, 18] are well-recognized issues in CKD, with studies in
patients on hemodialysis suggesting that reducing sodium
intake may lead to a decrease in fluid retention between
dialysis sessions [19, 20]. Phosphate retention is part of the
complex mineral and bone disorder of CKD and is asso-
ciated with abnormalities in bone turnover and mineral-
ization and in vascular or other soft-tissue calcification
[21]. Hyperphosphatemia is associated with increased
mortality in patients with CKD [22–24]. Therefore,
reducing sodium and phosphate intake are important
components of guidelines for the management of patients
with CKD [15, 21, 25].
Our study also showed that repeated-dose tenapanor
treatment (up to 90 mg twice daily for 7 days) in Japanese
individuals resulted in increases relative to placebo in mean
stool phosphorus content that were of a similar magnitude
to those observed in a healthy volunteer study of the
phosphate binder sevelamer at a dose of 5 g three times
daily for 4 days [26]. Tenapanor may, therefore, have
potential as a future treatment modality for hyperphos-
phatemia by improving phosphate control and reducing
tablet burden and sodium uptake. The precise mechanism
of action of tenapanor with regard to reducing phosphate
absorption is currently being evaluated.
Phase 2 trials evaluated the potential clinical benefits of
reducing sodium and phosphate absorption by tenapanor
treatment in patients with CKD [27–29]. A study in
patients with CKD stage 5D (hemodialysis) on the effects
of tenapanor on fluid overload [27], and another in patients
with type 2 diabetes mellitus and CKD stage 3 on the effect
of tenapanor on albuminuria (a marker of renal function
decline) [29], did not meet their primary objectives.
However, results from a 4-week study in patients with
hyperphosphatemia in CKD stage 5D (hemodialysis), show
the effects of tenapanor on phosphate absorption translate
into clinically meaningful reductions in serum phosphate
levels [28].
Tenapanor reduces intestinal sodium absorption, leading
to enhanced intestinal fluid volume and transit, as
demonstrated by the softer stool consistency and increase
in frequency of bowel movements observed in the present
study. Tenapanor has also been shown to have an anti-
nociceptive effect in an IBS animal model of visceral pain
[30], and it is also being evaluated in constipation-pre-
dominant IBS [31, 32]. Results from a phase 2b study of
tenapanor indicate that these effects translate into clinically
meaningful improvements in constipation and abdominal
pain in patients with constipation-predominant IBS [33].
The safety and tolerability profiles and pharmacody-
namic effects of tenapanor seen in this study in Japanese
individuals are consistent with those observed in the Cau-
casian individuals in this study, and also in other healthy
volunteers in study populations consisting mainly of Cau-
casian and African-American participants [5, 7]. Our study
included a group of Caucasian individuals, who received
the highest dose of tenapanor (90 mg twice daily for
7 days), primarily to generate additional safety data at the
highest dose, including digital ECG measurements. This is
important from a global development perspective. This
study found no evidence of any clinically significant effects
Clin Exp Nephrol
123
on digital ECG measurements in either the Japanese or the
Caucasian individuals receiving tenapanor. The most
common adverse events in individuals receiving tenapanor
that were judged by the study investigator as being related
to treatment were gastrointestinal in nature, with diarrhea
being the most frequent event. The occurrence of adverse
events such as diarrhea following tenapanor treatment may
be expected, given the pharmacological effect that leads to
increased water retention in the gastrointestinal tract. This
is also reflected in the observation that tenapanor treatment
resulted in softer stools compared with placebo in all
treatment groups in this study, which is consistent with data
from other healthy volunteer studies of tenapanor [5].
This study in Japanese participants was conducted in the
USA in Japanese people who had lived outside Japan for
less than 5 years. It is difficult to judge whether different
results would have been obtained if the study had been
conducted in Japan because it is unclear whether these
individuals had changed their diet since leaving Japan.
Notwithstanding these considerations, all participants
received a diet standardized for sodium content during the
study, including during the run-in period. No other food
items, spices, or additional table salt was allowed, thereby
ensuring controlled sodium intake. Although the diet was
not standardized for phosphate content, all participants did
receive the same meals on the same study days, thereby
facilitating consistent phosphate intake.
In conclusion, tenapanor treatment resulted in reduc-
tions in absorption of sodium and phosphate from the gut in
healthy Japanese volunteers. Tenapanor had minimal sys-
temic exposure, was well tolerated, and produced a softer
stool consistency. Further evaluation of tenapanor in dif-
ferent patient groups with hyperphosphatemia in CKD
requiring dialysis and patients with constipation-predomi-
nant IBS is warranted.
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